Ligand Pharmaceuticals Incorporated (LGND)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
As of 11:54AM EDT. Market open.
| Previous Close | 72.83 |
| Open | 73.50 |
| Bid | 74.42 x 100 |
| Ask | 74.81 x 100 |
| Day's Range | 73.37 - 74.68 |
| 52 Week Range | 49.24 - 94.57 |
| Volume | |
| Avg. Volume | 180,281 |
| Market Cap | 1.341B |
| Beta (5Y Monthly) | 0.92 |
| PE Ratio (TTM) | 24.64 |
| EPS (TTM) | 3.03 |
| Earnings Date | May 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jul 02, 2010 |
| 1y Target Est | 116.80 |
Business WireLigand and Agenus Enter Into $100 Million Royalty Financing Agreement
JUPITER, Fla. and LEXINGTON, Mass., May 07, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) and Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the companies have entered into a royalty financing agreement to support Agenus’ key development initiatives in the ongoing BOT/BAL clinical development program, including its planned confirmatory Phase 3 trial in its lead indication of patients with met
ZacksZacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand have been highlighted in this Industry Outlook article.
ZacksDon't Overlook These Top Medical Stocks as Q1 Earnings Approach
Several top-rated Zacks Medical sector stocks are standing out ahead of their quarterly reports on Tuesday, May 7.
© 2024 Yahoo. All rights reserved.